tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

AMGN Stock Latest News

Veeva’s Clinical Platform selected by Amgen
The FlyVeeva’s Clinical Platform selected by Amgen
5d ago
AMGN
VEEV
Amgen’s Repatha: Balancing Growth Potential with Long-Term Risks
PremiumRatings
Amgen’s Repatha: Balancing Growth Potential with Long-Term Risks
5d ago
AMGN
Royalty Pharma Stock (RPRX) Rises as it Seals $950M Cancer Royalties Deal with Amgen
PremiumMarket News
Royalty Pharma Stock (RPRX) Rises as it Seals $950M Cancer Royalties Deal with Amgen
7d ago
ONC
AMGN
Amgen says FDA broadens the approved use of Repatha
PremiumThe Fly
Amgen says FDA broadens the approved use of Repatha
8d ago
AMGN
Amgen price target raised to $342 from $328 at Piper Sandler
PremiumThe Fly
Amgen price target raised to $342 from $328 at Piper Sandler
8d ago
AMGN
Royalty Pharma confirms acquisition of royalty interest in Amgen’s Imdelltra
PremiumThe FlyRoyalty Pharma confirms acquisition of royalty interest in Amgen’s Imdelltra
8d ago
ONC
AMGN
BeOne Medicines to sell royalty rights of Imdelltra to Royalty Pharma for $950M
Premium
The Fly
BeOne Medicines to sell royalty rights of Imdelltra to Royalty Pharma for $950M
8d ago
ONC
AMGN
Amgen’s New Clinical Study: A Potential Game Changer in Lung Cancer Treatment
Premium
Company Announcements
Amgen’s New Clinical Study: A Potential Game Changer in Lung Cancer Treatment
11d ago
AMGN
Amgen’s Promising Asthma Treatment: Rocatinlimab Study Update
PremiumCompany Announcements
Amgen’s Promising Asthma Treatment: Rocatinlimab Study Update
11d ago
AMGN
Amgen’s New Study on Bemarituzumab: A Potential Game-Changer in Gastric Cancer Treatment?
PremiumCompany Announcements
Amgen’s New Study on Bemarituzumab: A Potential Game-Changer in Gastric Cancer Treatment?
11d ago
AMGN
Amgen’s AMG 193 Study: A New Hope for Advanced Thoracic Tumors
PremiumCompany Announcements
Amgen’s AMG 193 Study: A New Hope for Advanced Thoracic Tumors
11d ago
AMGN
Amgen’s Dazodalibep Study: A Promising Step for Sjögren’s Syndrome Treatment
PremiumCompany Announcements
Amgen’s Dazodalibep Study: A Promising Step for Sjögren’s Syndrome Treatment
11d ago
AMGN
Amgen’s Latest Clinical Study: A New Front-Line Therapy for Lung Cancer?
PremiumCompany AnnouncementsAmgen’s Latest Clinical Study: A New Front-Line Therapy for Lung Cancer?
11d ago
AMGN
Amgen’s Phase 2 Study on HZN-1116: A Potential Breakthrough for Sjögren’s Syndrome
Premium
Company Announcements
Amgen’s Phase 2 Study on HZN-1116: A Potential Breakthrough for Sjögren’s Syndrome
11d ago
AMGN
Amgen’s Phase 3 Study on Tarlatamab and Durvalumab: A Potential Game-Changer in Lung Cancer Treatment
Premium
Company Announcements
Amgen’s Phase 3 Study on Tarlatamab and Durvalumab: A Potential Game-Changer in Lung Cancer Treatment
11d ago
AMGN
Amgen’s AMG 193 Study: A Potential Game-Changer for Advanced NSCLC Treatment
PremiumCompany Announcements
Amgen’s AMG 193 Study: A Potential Game-Changer for Advanced NSCLC Treatment
11d ago
AMGN
Amgen and AstraZeneca Launch Promising Phase 3 Lung Cancer Study
PremiumCompany Announcements
Amgen and AstraZeneca Launch Promising Phase 3 Lung Cancer Study
11d ago
AZN
AMGN
Amgen’s Promising Phase 3 Study on Dazodalibep for Sjögren’s Syndrome
PremiumCompany Announcements
Amgen’s Promising Phase 3 Study on Dazodalibep for Sjögren’s Syndrome
11d ago
AMGN
Amgen’s Avacopan Study: A Potential Game Changer for Autoimmune Treatments
PremiumCompany Announcements
Amgen’s Avacopan Study: A Potential Game Changer for Autoimmune Treatments
11d ago
AMGN
Amgen’s Tarlatamab Study: A New Hope for Small Cell Lung Cancer
PremiumCompany AnnouncementsAmgen’s Tarlatamab Study: A New Hope for Small Cell Lung Cancer
12d ago
AMGN
Amgen’s New Study on Tarlatamab and AB248: A Potential Game-Changer for Lung Cancer Treatment
Premium
Company Announcements
Amgen’s New Study on Tarlatamab and AB248: A Potential Game-Changer for Lung Cancer Treatment
13d ago
AMGN
Amgen’s KRAS Mutation Study: A Potential Game-Changer in Colorectal Cancer Treatment
Premium
Company Announcements
Amgen’s KRAS Mutation Study: A Potential Game-Changer in Colorectal Cancer Treatment
18d ago
AMGN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >